Last reviewed · How we verify
Placebo+Standard Therapy
This drug is a placebo in combination with standard therapy.
This drug is a placebo in combination with standard therapy. Used for Various conditions.
At a glance
| Generic name | Placebo+Standard Therapy |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The placebo component does not have a known mechanism of action, while the standard therapy is a treatment that is already established and widely used.
Approved indications
- Various conditions
Common side effects
Key clinical trials
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (PHASE1)
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo+Standard Therapy CI brief — competitive landscape report
- Placebo+Standard Therapy updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI